Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investors should review the accompanying press release for reported figures and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 EMPEROR enrollment complete at 162 patients, with primary data readout expected Q3 2027 and rolling U.S. NDA completion targeted H2 2027
- FDA pre-NDA meeting planned H2 2026, with rolling U.S. NDA submission targeted Q1 2027
- Liquidity $420.0M, including $354.3M at June 30 plus $65.7M ATM proceeds, expected to fund operations through potential early-2028 commercialization
- Q2 revenue fell to $9.3M from $13.8M, while net loss widened to $61.6M from $23.5M
- R&D spending rose to $49.5M and SG&A to $25.3M, reflecting Phase 3 advancement and commercial launch preparation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.